Skip to main content

Alert COVID-19

Please find service updates and current visiting rules in our COVID-19 section.

This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.

The effect of atomoxetine on learning and memory in healthy volunteers

Volunteers needed for a study investigating the effects of a drug called 'atomoxetine' on learning and memory.

Trial categories: Brain

Sponsoring organisation: CTRG, University of Oxford

The drug, atomoxetine, is commonly used to treat ADHD.

We are looking for healthy participants (both male and female), aged 18 to 35 years. In order to participate, you must be in good health with no history of neurological or psychiatric conditions.

The study consists of up to 3 study visits.

The first and second study visits will take place at the Department of Psychiatry (Warneford Hospital), each lasting between 3 and 4 hours. On either the first or second study visit you will be given a single dose of the drug called atomoxetine.

On the alternate visit you will be given a placebo treatment. After receiving either the drug or placebo treatment you will be asked to perform a computerised behavioural task and undergo an MRI scan, a type of non-invasive scan that allows us to see how the brain stores and uses memories. This scan is safe and does not involve any needles or injections.

During the third study visit, which will take place at either the Department of Psychiatry (Warneford Hospital) or at the Oxford Centre for Functional MRI of the Brain (FMRIB, at the John Radcliffe hospital), you will perform computerised behavioural tasks, lasting no more than 1.5 hours.

After the last study session you will be reimbursed for your time.

Prior to your participation you will be asked questions about your medical history to check your suitability for the study, including whether it is safe for you to go in an MRI scanner.

If you are interested and would like more information, please contact Ms Renée Koolschijn

at the Wellcome Centre for Integrative Neuroimaging.